Our findings reveal that elevated IL1RAP expression strongly correlates with FLT3-ITD mutations and predicts poor clinical outcomes, including reduced overall and relapse-free survival in intermediate-risk AML patients. Here, IL1RAP is linked to acute myeloid leukemia.